Get news on conferences, trials, symposium invites, and more. Sign up for updates
Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Order lookup
Reimbursement resources
Customer support

Call customer care

1 (888) 272-1001

TheraSphere Y-90 Glass Microsphere glowing against blue background. TheraSphere sphere on blue background

TheraSphere™ Y-90 Glass Microspheres

Control for durable outcomes

TheraSphere is a targeted radioembolization therapy made of glass microspheres containing radioactive Yttrium-90 (Y-90). Designed for control to achieve durable patient outcomes, TheraSphere preserves quality of life and provides reproducible results for treating and referring physicians. As an FDA-approved Y-90 therapy for HCC, it is a cost-effective procedure backed by committed support from the industry leader, Boston Scientific.

Learn more about TheraSphere
Contact us

Any Day Dosing, Powered by TheraSphere 360

More days. More options. More control.

Deliver a proven dose, any day of the week. With Any Day Dosing, you have more days to treat on your schedule, more options to treat with the dose you want, and more control over your treatment plan. Available exclusively on TheraSphere 360, Any Day Dosing allows you to plan treatments around your patients and your schedule – no compromises, no added products or processes. The same TheraSphere – ready when you are.

Experience an interactive demo

Durability leads to quality of life

Confidently destroy tumor cells with proven ablative dosing and a good patient safety profile.1

View clinical data
icon-person-with-medical-symbol.

Referring physicians

Cancer care is multidisciplinary. TheraSphere is a minimally invasive, well-tolerated interventional treatment for your patients with hepatocellular carcinoma. It provides proven tumor control with predictable outcomes that helps maintain patients' quality of life, while preserving future treatment options.² 

 

View referring physician information
icon-truck

Get started with TheraSphere

Close the loop and power the practice with TheraSphere 360, a unified digital platform you and your Y-90 care team can access from anywhere. Dose, order, view inventory, and track details in real time, and get personalized practice data to make more informed treatment and referral decisions. 

Request a demo

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

See reimbursement resources

References

  1. LEGACY: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
  2. Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y-90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827. https://doi.org/10.1007/s00259-019-04588-x.

*Refers to HCC or associated tumors .

TheraSphere indications, safety, and warnings
TheraSphere 360 indications, safety, and warnings

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.